RxDoctor Payments Data

Desiree Davis

Adult Health · Vanceboro, NCNPI 1215493572

Payments from drug & device makers

$739in general payments, 2019–2025

Across 37 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$208
  • Bayer$124
  • AstraZeneca$99
  • Boehringer Ingelheim$69
  • GSK$57
  • Amgen$39
  • plus $142 from 7 others

What the payments were for

  • Food & beverage$739100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$739 in reported general payments places this provider in the 55th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$77,667
Medicare patients
190
Services billed
2,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol126$107,376
OzempicSemaglutide38$57,449
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$55,278
EliquisApixaban58$48,379
TrulicityDulaglutide38$48,102
JardianceEmpagliflozin41$43,062
MounjaroTirzepatide30$31,495
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$30,966
EntrestoSacubitril/Valsartan31$29,133
RybelsusSemaglutide17$27,515
LinzessLinaclotide24$26,281
JanuviaSitagliptin Phosphate12$17,394
KerendiaFinerenone12$14,516
XareltoRivaroxaban11$9,257
SymbicortBudesonide/Formoterol Fumarate18$5,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$99$143,675187 claims
Novo NordiskOzempic, Rybelsus$208$84,96455 claims
Lilly USA, LLCTrulicity, Mounjaro$36$79,59768 claims
GSKTrelegy Ellipta$57$55,27858 claims
PfizerEliquis$14$48,37958 claims
Boehringer IngelheimJardiance$69$43,06241 claims
AbbVieLinzess, Synthroid$15$27,38335 claims
BayerKerendia$124$14,51612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 614 adult health providers in North Carolina.

Other adult health in Vanceboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →